Bruker Daltonics and Queensland Institute of Medical Research Expand Collaboration with Installation of maXisâ„¢ UHR-TOF
January 05 2009 - 7:00AM
Business Wire
Bruker Daltonics and the Queensland Institute of Medical Research
(QIMR) announced today the installation of the first maXis�
Ultra-High Resolution Time-Of-Flight (UHR-TOF) mass spectrometer in
Australasia, thereby further strengthening the collaboration
between Bruker and one of the premier medical research institutes
in Australia. maXis is the only instrument available today that
uniquely combines the previously incompatible trends in modern mass
spectrometry of ultra-high resolution and very fast chromatographic
separations. Exceptional mass accuracy, high resolution and
sensitivity are maintained even when coupled to the fastest liquid
chromatography systems. maXis has already been proven as an
exceptional tool in quantitative proteomics, peptide and intact
protein analysis as well as on-the-fly unambiguous small molecule
identification using the unique Smartformula� 3D method. �Bruker is
delighted to further strengthen the collaborative relationship we
have developed with Professor Gorman and QIMR. The installation of
maXis, the first in Australasia, offers a major opportunity for us
to co-develop the advanced methodologies required for the wide
range of applications undertaken at QIMR�s Protein Discovery Centre
(PDC),� stated Clive Seymour, Executive Vice President of Bruker
Daltonics. "The installation of maXis will allow us to collaborate
more extensively with Bruker, particularly in the development of
ETD methodologies for the study of post-translational modifications
on this exciting new platform, and represents a quantum leap in MS
capability at QIMR,� commented Professor Jeff Gorman, Director of
the PDC. He continued: �maXis completes the stable of high
resolution mass spectrometers within the facility and is a brand
new technology advancing Australian science at QIMR. maXis will add
significantly to the capability of the PDC to participate in the
Australian government National Collaborative Research
Infrastructure Scheme, funded through Bioplatforms Australia and
the Queensland Government. In particular, it will provide the PDC
with the scope to collaborate more effectively with scientists from
QIMR, Australia and internationally on projects aimed at combating
infectious diseases and cancer.� For more information about Bruker
Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit
www.bdal.com and www.bruker.com.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Oct 2023 to Oct 2024